Surrozen Inc
SRZNW0.022USD
+0.006+38.27%
Close 04/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Surrozen Inc Company
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Company Info
Company codeSRZNW
Company nameSurrozen Inc
IPO dateNov 23, 2020
Founded at2021
CEOMr. Craig C. Parker
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address171 Oyster Point Blvd
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16504752820
Websitehttps://www.surrozen.com
Company codeSRZNW
IPO dateNov 23, 2020
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Company Secretary
Chief Financial Officer, Chief Operating Officer, Company Secretary
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
--
--
Dr. David J. Woodhouse, Ph.D.
Dr. David J. Woodhouse, Ph.D.
Non-Executive Chairman of the Board, Independent Director
Non-Executive Chairman of the Board, Independent Director
--
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Company Secretary
Chief Financial Officer, Chief Operating Officer, Company Secretary
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, Feb 28
Update time: Fri, Feb 28
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
28
2.89M
0.00%
-639.43K
2024Q4
28
2.89M
0.00%
-639.43K
2024Q3
30
2.68M
0.00%
-1.42M
2024Q2
29
4.64M
0.00%
-229.29K
2024Q1
27
4.54M
0.00%
-721.56K
2023Q4
27
4.59M
0.00%
-580.20K
2023Q3
24
5.00M
0.00%
-35.88K
2023Q2
22
4.87M
0.00%
-224.97K
2023Q1
23
4.88M
0.00%
-106.68K
2022Q4
23
4.77M
0.00%
-375.46K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Boxer Capital Management, LLC
66.67K
0%
--
--
Dec 31, 2024
Baker Bros. Advisors LP
833.33K
0%
--
--
Dec 31, 2024
LMR Partners LLP
648.28K
0%
+648.28K
--
Dec 31, 2024
Bridger Management, LLC
466.67K
0%
--
--
Dec 31, 2024
Euclidean Capital, L.L.C.
170.83K
0%
--
--
Dec 31, 2024
Perceptive Advisors LLC
166.67K
0%
--
--
Dec 31, 2024
Deerfield Management Company, L.P.
166.67K
0%
--
--
Dec 31, 2024
Samsara BioCapital, LLC
100.00K
0%
--
--
Dec 31, 2024
Cantor Fitzgerald, L.P
70.82K
0%
+35.62K
+101.20%
Dec 31, 2024
EcoR1 Capital, LLC
66.67K
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data